IMRT better for sparing bladder when treating prostate cancer

When treating early-stage prostate cancer, intensity modulated radiation therapy (IMRT) spares the bladder significantly more from direct radiation when compared to 3-D conformal proton therapy (3D-CPT), but the amount of rectal sparing is similar with both treatments, according to a study released in the October issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

“This study was important because it reassures a patient with prostate cancer that the methods that are available at his local hospital may, in many cases, be as good as those that are currently only available in a limited number of centers,” said Anthony L. Zietman, M.D., a professor of radiation oncology at Harvard Medical School and a radiation oncologist at Massachusetts General Hospital.

According to the American Cancer Society, approximately 218,890 new cases of prostate cancer will be diagnosed in the United States in 2007. One in six men will get prostate cancer in his lifetime; however, only one in 35 men will die from the disease due in part to the wide variety of treatment options available.

The Massachusetts General Hospital Department of Radiation Oncology and Harvard Medical School, both in Boston, jointly conducted the study to determine the comparative dosimetric benefits and drawbacks of IMRT versus 3D-CPT as treatments for patients with prostate cancer and to determine whether specific cases should be assigned to one treatment method over the other. The study sought to identify the sites in which proton therapy offers an advantage over IMRT; IMRT is a readily available form of treatment, but proton therapy is only available at five treatment centers in the United States.

Ten patients with clinically-localized early-stage prostate cancer were randomly selected for the study and treated with both IMRT and 3D-CPT. The percentage of bladder volumes receiving more than 70 Gy/CGE was reduced by an average of 34 percent when using IMRT versus 3D-CPT, but the rectal volumes were found to be equivalent.

Source: American Society for Therapeutic Radiology and Oncology

Related stories:

Precision Radiation Can Destroy Tumors That Surgery Cannot Reach
Debora Tisdale didn't want to lose her heart in the process of saving her cancerous breast. She feared that during radiation treatment, the searing beams intended to attack her breast tumor could also inadvertently strike her healthy heart.
Facts About Prostate Cancer and Its Treatment
In 2006, about 235,000 Americans will be diagnosed with prostate cancer, making it the most common cancer among males. If caught early, prostate cancer is very treatable and usually curable.
Overweight men face higher risk of dying of prostate cancer
(PhysOrg.com) -- Prostate cancer patients who are overweight and have elevated insulin levels are much more likely to die of the cancer than other patients, say researchers at Harvard University and McGill University. Their research is published in the October issue of The Lancet Oncology.
New catheter-less technique may ease the pain and discomfort of prostate cancer recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.
Raised risk of prostate cancer in Black men
(PhysOrg.com) -- Black men living in England are three times more likely to get prostate cancer than White men and tend to be diagnosed five years younger, researchers have found.
Disease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
Deactivating a cancer growth promoter
Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at Baylor College of Medicine in a report that appears in the current issue of the journal Molecular Cell.
Racial disparities decline for cancer in Missouri
Cancer death rates in the United States are highest among African Americans, but a new report shows that in Missouri the disparity in cancer incidence and death between African Americans and whites is declining. As a result, cancer incidence (the rate of newly diagnosed cases) between the races is equal, although the death rate will probably remain higher for African Americans for some time.

News discussion:

Medicine & Health news